《新股消息》內地兩企昨通過上市聆訊 料短期內或開展招股程序
內地天然氣營運商交運燃氣及心臟病介入醫療器械供應商樂普心泰醫療,昨日(25日)通過上市聆訊,預料短期內或會開展招股程序。
交運燃氣今年首四個月盈利1,131.8萬元人民幣(下同),按年跌25.79%;收入1.58億元,按年升16.39%;毛利率按年下降4.3個百分點至14.4%;興證國際(06058.HK)為獨家保薦人。集資所得將用於建設新中壓管道;升級城巿管道網絡;為經營區域用戶將現有燃氣錶更換為金卡錶;用作營運資金及其他一般公司用途等。
另外,樂普心泰醫療今年上半年盈利2,425.5萬元,按年跌41.92%;收入1.24億元,按年增12.46%;研發開支按年上升19.4%至1,963.7萬元;毛利率87.7%,按年稍跌1.6個百分點;深圳上市公司樂普醫療為該公司控股股東,直接持有公司85.48%的股份;中金公司(03908.HK)為獨家保薦人。(ca/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.